Cytoprotective Effect of Astaxanthin in a Model of Normal Intraocular Pressure Glaucoma.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
07
2020
revised:
04
09
2020
accepted:
12
09
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Glaucoma is characterized by axonal degeneration of retinal ganglion cells (RGCs) and apoptotic death of their cell bodies. Lowering intraocular pressure is currently the only way to treat glaucoma, but it is often insufficient to inhibit the progression of the disease. Glaucoma is a multifactorial disease, and the involvement of oxidative stress has recently received much attention. In the present study, we investigated the cytoprotective effect of astaxanthin (AST) on RGC degeneration using a normal-tension glaucoma (NTG) mouse model, which lacks the
Identifiants
pubmed: 33014448
doi: 10.1155/2020/9539681
pmc: PMC7520698
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9539681Informations de copyright
Copyright © 2020 Kasumi Kikuchi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1940-4
pubmed: 10845620
Arch Ophthalmol. 1996 Mar;114(3):299-305
pubmed: 8600890
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):877-83
pubmed: 15728543
Ophthalmology. 2002 Apr;109(4):766-70
pubmed: 11927438
Altern Med Rev. 2011 Dec;16(4):355-64
pubmed: 22214255
Curr Eye Res. 2014 Aug;39(8):823-9
pubmed: 24912005
Cell Death Differ. 2013 Sep;20(9):1250-6
pubmed: 23852370
Am J Med. 2003 Jun 1;114(8):638-46
pubmed: 12798451
Am J Ophthalmol. 2000 Nov;130(5):589-96
pubmed: 11078837
PLoS One. 2016 Dec 1;11(12):e0166915
pubmed: 27907028
Curr Med Chem. 2011;18(6):931-42
pubmed: 21182473
Pharmacol Res. 2018 Oct;136:1-20
pubmed: 30121358
Biol Pharm Bull. 2011;34(6):839-44
pubmed: 21628881
Am J Ophthalmol. 1998 Oct;126(4):487-97
pubmed: 9780093
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
Ophthalmology. 2004 Sep;111(9):1641-8
pubmed: 15350316
Mar Drugs. 2020 Jan 28;18(2):
pubmed: 32012819
Curr Opin Pharmacol. 2013 Feb;13(1):16-22
pubmed: 22999653
Mar Drugs. 2020 May 01;18(5):
pubmed: 32370045
Mar Drugs. 2013 Mar 21;11(3):960-74
pubmed: 23519150
Neurosci Lett. 2015 Feb 19;588:108-13
pubmed: 25555796
Regul Toxicol Pharmacol. 2010 Oct;58(1):121-30
pubmed: 20457203
Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41
pubmed: 26990581
Heliyon. 2016 Oct 28;2(10):e00191
pubmed: 27861646
Mol Vis. 2014 Dec 31;20:1796-805
pubmed: 25593507
Curr Eye Res. 2016 Nov;41(11):1465-1472
pubmed: 27158842
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Arch Ophthalmol. 2010 Mar;128(3):276-87
pubmed: 20212196
Exp Eye Res. 2006 Feb;82(2):275-81
pubmed: 16126197
Surv Ophthalmol. 2018 Jan - Feb;63(1):56-74
pubmed: 28666629
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Eye Vis (Lond). 2020 Mar 10;7:15
pubmed: 32175441
Mol Nutr Food Res. 2011 Jan;55(1):150-65
pubmed: 21207519
Am J Ophthalmol. 2004 Jan;137(1):62-9
pubmed: 14700645
Mar Drugs. 2014 Jan 07;12(1):128-52
pubmed: 24402174
J Clin Invest. 2007 Jul;117(7):1763-70
pubmed: 17607354
J Immunol. 2004 Feb 15;172(4):2522-9
pubmed: 14764725